Item 5.07. Submission of Matters to a Vote of Security Holders.

On August 6, 2019, CURE Pharmaceutical Holding Corp., a Nevada corporation (the “Company”) held an annual meeting of stockholders (the “Annual Meeting”) at the Company’s corporate office located at 1620 Beacon Place, Oxnard, California 93033. At the Annual Meeting, the stockholders voted on the following proposals described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on July 12, 2019. As of the record date for the Annual Meeting, there were 43,445,151 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), issued and outstanding and entitled to one vote for each share held. The holders of 63.84 % of the Company’s shares of common stock outstanding submitted votes by proxy or in person at the Annual Meeting, constituting a quorum. Set forth below are the final voting results for each of the proposals:

Proposal 1: Election of Directors

The Company’s stockholders elected Robert Davidson, William Yuan, Gene Salkind, M.D., Ruben King-Shaw, Jr., Joshua Held, Lauren Chung Ph.D., and Anya Goldin as directors, to hold office until the 2020 Annual Meeting of stockholders and until their respective successors are duly elected and qualified. Each director nominee received more “FOR” votes than “WITHHOLD” votes. The following table shows the number of votes cast “FOR” or “WITHHOLD” and the number of “ABSTENTIONS” and “BROKER NON-VOTES” for each nominee:

Proposal 2: Approval of the Reincorporation of the Company from the State of Nevada to the State of Delaware

The reincorporation of the Company from the State of Nevada to the State of Delaware was approved by the Company’s stockholders and the voting results of the shares of the Company’s Common Stock were as follows:

Proposal 3: Amendment to the Company’s Articles of Incorporation to Increase the Number of Authorized Shares of the Company’s Common Stock by 75,000,000 Shares to 150,000,000 Shares

An amendment to the Company’s Articles of Incorporation to increase the number of authorized shares of the Company’s Common Stock by 75,000,000 shares to 150,000,000 shares was approved and the voting results of the shares of the Company’s Common Stock were as follows:

Proposal 4: Amendment to the Company’s 2017 Equity Incentive Plan to Increase the Number of Shares of the Company’s Common Stock Available for Awards thereunder by an Additional 5,000,000 Shares to a Total of 10,000,000 Shares

An amendment to the Company’s 2017 Equity Incentive Plan to increase the number of shares of the Company’s common stock available for awards thereunder by an additional 5,000,000 shares to a total of 10,000,000 shares was approved and the voting results of the shares of the Company’s Common Stock were as follows:

Proposal 5: Amendment to the Company’s 2017 Equity Incentive Plan to Revise Section 5.5 of the 2017 Equity Incentive Plan Relating to Nonemployee Director Award Limits

An amendment to the Company’s 2017 Equity Incentive Plan to revise Section 5.5 of the Equity Incentive Plan relating to nonemployee director award limits was approved and the voting results of the shares of the Company’s Common Stock were as follows:

Proposal 6: Ratification of Auditors

The Company’s stockholders ratified the appointment of RBSM LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The following table shows the tabulation of the votes cast “FOR” and “AGAINST” this proposal as well as “ABSTENTIONS” submitted on this proposal: